89bio, Inc. (ETNB) Financials

ETNB Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 596.3 million 60.0 million
2023-09-30 460.1 million 49.9 million
2023-06-30 492.5 million 50.5 million
2023-03-31 494.3 million 48.5 million

ETNB Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -34.3 million 4.0 million
2023-09-30 -30.4 million 4.4 million
2023-06-30 -34.4 million 4.1 million
2023-03-31 -30.1 million 3.6 million

ETNB Net Income

No data available :(

ETNB Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 578.9 million - 2.3 million
2023-09-30 448.3 million - 229000
2023-06-30 478.0 million 24.5 million 271000
2023-03-31 480.9 million 24.3 million 313000

ETNB Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 80.7 million
2023-09-30 76.3 million
2023-06-30 74.1 million
2023-03-31 53.2 million

ETNB Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 4000 33.6 million 7.6 million 16000
2023-09-30 - 31.4 million 7.9 million -
2023-06-30 - 34.9 million 7.2 million -
2023-03-31 - 22.3 million 6.2 million -

ETNB Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 - 16000
2023-09-30 - 10000
2023-06-30 - 52000
2023-03-31 - 55000

ETNB

Price: $8.26

52 week price:
6.58
22.93

Earnings Per Share: -2.00 USD

P/E Ratio: -5.21

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 1.6 million

Market Capitalization: 1.0 billion

Links: